Skip to search boxSkip to navigationSkip to main content

Adenosine stimulation of Na+ transport is mediated by an A1 receptor and a [Ca2+]i-dependent mechanism

  • John P. Hayslett(corresponding author)
    ,
  • Lawrence J. Macala
    ,
  • Joan I. Smallwood
    ,
  • Leena Kalghatgi
    ,
  • Jose Gasalla-Herraiz
    ,
*Corresponding author for this work
Scholary Output:
Contribution to journal
Article
Peer-review

Open access

Abstract

Studies were performed to determine the primary signal transduction mechanism that mediates adenosine stimulation of electrogenic sodium transport in renal epithelial cells. Experiments were performed on cultured amphibian A6 cells with an adenosine analogue that preferentially binds to the A1 receptor, cyclohexyladenosine (CHA). Sodium transport was assessed by the equivalent short circuit current (Ieq). CHA was found to stimulate Ieq via activation of an A1 receptor because (1) the threshold concentration was 1 nM compared to that of 10 μM for the specific A2 agonist CGS21680, (2) CHA inhibited vasopressin (AVP)-stimulated cAMP production by a pertussis toxin-sensitive mechanism, and (3) the action of CHA was inhibited by the A1 antagonist 1,3-dipropyl-8-cyclopentylxanthine (DPCPX). CHA increased intracellular Ca2+ ([Ca2+]i) and stimulated phosphoinositide turnover at concentrations that increased Ieq and in a time course that paralleled the increase in Ieq. Ion transport was stimulated by a Ca2+-dependent mechanism because the CHA induced increase in Ieq was inhibited by chelating [Ca2+]i with 5,5′dimethyl BAPTA in a dose-dependent manner, with a Ki of approximately 10 μM. The increase in Ieq was also dose-dependently inhibited by the specific PKC inhibitors dihydroxychlorpromazine and chelerythrine, and by trifluoperazine which inhibits PKC and calmodulin. Further studies indicated that CHA-stimulated Ieq was independent of cAMP generation because CHA did not induce an increase in cAMP accummulation parallel to the increase in Ieq in a dose-response analysis, and the adenylate cyclase inhibitor 2′,5′ dideoxy-adenosine (DDA) did not affect the CHA-induced increase in Ieq. These studies indicate, therefore, that adenosine stimulation of Ieq occurs, at least in part, through calcium-dependent signal transduction events and not through regulation of adenylate cyclase.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 1576-1584 (9 pages)

Journal (Volume, Issue Number)

Kidney International (Volume 47, Issue 6)

Publication milestones

  • Published - 06/1995

Publication status

Published - 06/1995

ISSN

0085-2538

Publication IDs

  • Scopus: 0028999197
  • PubMed: 7643526

Publication metrics

Metrics

Scopus
citations
Fractional count
1
Fractional count
0.17
Fractional count
5
Fractional count
0.83
Fractional count
1
Fractional count
1

PlumX, opens in new tab

Citation count
30
Captures
5

Funding Details

This study was supported by the National Institutes of Health grant DK 18061. Dr. Gasalla-Herraiz was supported by a grant from Fondo de Investigacion Sanitaria Ia Seguridad Social of Spain, and Dr. Isales was supported by Award DK-19813. The authors are grateful to M. Tara- gowski and M. Pucci for the preparation of the manuscript and figures. Reagents Arginine vasopressin (AVP), adenosine deaminase (ADA; Type V-bovine spleen), trifluoperazmne (TFP), 1,1,2-Trichiorotri-fluoroethane and tri-N-octylamine were obtained from Sigma (St. Louis, MO, USA). Additional chemicals were obtained from the following vendors: cyclohexyladenosine (CHA), Boehringer- Mannheim (Indianapolis, IN, USA); chelerythrine and forskolin (Calbiochem, La Jolla, CA, USA); 2',5' dideoxyadenosine (DDA) (Pharniacia, Milwaukee, WI, USA); 1,3-dipropyl-8-cyciopentylxan- thine (DPCPX) and CGS21680, RBI, (Natick, MA, USA); pertussis toxin, List Biologicals (Campbell, CA, USA); Ro-201724 (Biomol Research Lab, Inc. Plymouth Meeting, PA, USA); amiloride was a gift from Merck Sharp & Dohme Research Labs (Rahway, NJ, USA) and 7,8-dihydroxychiorpromazine was provided by Research Bio-chemical, Inc., as part of the Chemical Synthesis Program of the National Institute of Mental Health, Contract 278—90-007 (BS).